AKR1B10 Antibody (monoclonal) (M01)
Mouse monoclonal antibody raised against a partial recombinant AKR1B10.
|Application ||WB, IHC, IF, E|
|Calculated MW||36020 Da|
|Other Names||Aldo-keto reductase family 1 member B10, 111-, ARL-1, Aldose reductase-like, Aldose reductase-related protein, ARP, hARP, Small intestine reductase, SI reductase, AKR1B10, AKR1B11|
|Target/Specificity||AKR1B10 (NP_064695, 76 a.a. ~ 143 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.|
|Format||Clear, colorless solution in phosphate buffered saline, pH 7.2 .|
|Storage||Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.|
|Precautions||AKR1B10 Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This gene encodes a member of the aldo/keto reductase superfamily, which consists of more than 40 known enzymes and proteins. This member can efficiently reduce aliphatic and aromatic aldehydes, and it is less active on hexoses. It is highly expressed in adrenal gland, small intestine, and colon, and may play an important role in liver carcinogenesis.
1.Aldo-Ketoreductase Family 1 B10 (AKR1B10) as A Biomarker to Distinguish Hepatocellular Carcinoma from Benign Liver Lesions.Matkowskyj KA, Bai H, Liao J, Zhang W, Li H, Rao S, Omary R, Yang GY.Human Pathology(2013) Volume 45, Issue 4, April 2014, Pages 834–8432.An integrated functional genomics approach identifies the regulatory network directed by brachyury (T) in chordoma.Nelson AC, Pillay N, Henderson S, Presneau N, Tirabosco R, Halai D, Berisha F, Flicek P, Stemple DL, Stern C, Wardle FC, Flanagan AM.J Pathol. 2012 Jul 30. doi: 10.1002/path.4082.3.A therapeutic method for the direct reprogramming of human liver cancer cells with only chemicals.Moriguchi H, Zhang Y, Mihara M, Sato C.Sci Rep. 2012;2:280. Epub 2012 Feb 21.4.Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma.Chung YT, Matkowskyj KA, Li H, Bai H, Zhang W, Tsao MS, Liao J, Yang GY.Mod Pathol. 2012 Jan 6. doi: 10.1038/modpathol.2011.191. [Epub ahead of print]5.AKR1B10 expression is associated with less aggressive hepatocellular carcinoma: a clinicopathological study of 168 cases.Schmitz KJ, Sotiropoulos GC, Baba HA, Schmid KW, Muller D, Paul A, Auer T, Gamerith G, Loeffler-Ragg J.Liver International DOI:10.1111/ j.1478-3231.2011. 02511.x6.Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin.Bains OS, Grigliatti TA, Reid RE, Riggs KW.J Pharmacol Exp Ther. 2010 Sep 13. [Epub ahead of print]7.Combined functional genome survey of therapeutic targets for hepatocellular carcinoma.Satow R, Shitashige M, Kanai Y, Takeshita F, Ojima H, Jigami T, Honda K, Kosuge T, Ochiya T, Hirohashi S, Yamada T.Clin Cancer Res. 2010 May 1;16(9):2518-28. Epub 2010 Apr 13.8.Proteomic Analysis of Bronchoalveolar Lavage Fluid Obtained from Rats Exposed to Formaldehyde.Ahn KH, Kim SK, Lee JM, Jeon HJ, Lee DH, Kim DK.JOURNAL OF HEALTH SCIENCE Vol. 56 (2010) , No. 3 287-295
If you have any additional inquiries please email technical services at firstname.lastname@example.org.